Jiangsu Alphamab Biopharmaceuticals Co., Ltd

This study tests a new drug combination (JSKN016 plus other treatments) in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. About 288 adults aged 18–75 will take part. The goal is to see if the combination shrinks tumors and to che…

This study tests a new drug called JSKN016 combined with chemotherapy or immunotherapy for people with advanced HER2-negative breast cancer that cannot be surgically removed or has spread. About 180 adults in China will join, and researchers will measure how many patients' tumors…

This study tests a new drug called JSKN016 against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The goal is to see if JSKN016 can slow cancer growth or extend survival. About 364 adults aged 18 …

This early-phase study is testing a new drug called JSKN022 in 225 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug c…

This study tests a new drug called JSKN003 against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. About 400 adults who have already tried at least one chemotherapy will be randomly assigned to get JSKN003 or a doctor-chosen chemo. The m…